BACKGROUND: Extrapulmonary neuroendocrine carcinomas (NECs) are poorly studied and are managed similar to lung NECs, which may not account for differences between the 2 groups of tumors as well as the heterogeneity within extrapulmonary NEC. METHODS: Data from the Surveillance, Epidemiology, and End Results program between 1973 and 2012 were used to estimate the relative percentages of lung NECs and subgroups of extrapulmonary NECs, epidemiological patterns at these sites, and the median and 5-year overall survival rates. RESULTS: Of 162,983 NEC cases, 14,732 were extrapulmonary; of these, 5509 were gastrointestinal (37.44%), 4151 were of unknown primary (28.2%), and 5072 were of other sites (34.4%). Lung NEC had the highest percentage of small cell morphology (95.2%) and gastrointestinal NEC had the least (38.7%), with the rest being other morphologies. Significant differences were noted with regard to median age (range, 48-74 years), percentage of cases of distant stage disease (24%-77%), and incidence according to sex and race. The median survival of patients with lung NEC was 7.6 months, that for patients with gastrointestinal NEC was 7.5 months (range, 25.1 months for NEC at the small intestine to 5.7 months for NEC at the pancreas), and that for patients with unknown NEC was 2.5 months. The 5-year survival rate for patients with local stage disease ranged from 58% to 60% for NECs of the female genital tract and small intestine to 25% for esophageal NECs. The primary tumor site remained statistically significant for survival even after adjusting for known prognostic variables (P<.0001). CONCLUSIONS: To the authors' knowledge, the current study is the largest study of NECs performed to date and also the first with comprehensive epidemiological data. Significant differences in incidence patterns and large variations in survival depending on anatomical site and morphological subtype were noted. A curative approach is possible for patients with nonmetastatic NECs. Cancer 2018;124:807-15.
INTRODUCTION
Neuroendocrine neoplasms are grouped into well-differentiated tumors or poorly differentiated carcinomas based on morphology and markers of proliferation in the latter, including the Ki-67 and/or mitotic index. [1] [2] [3] Within the poorly differentiated neuroendocrine carcinomas (NECs), lung NECs (including small cell and large cell carcinomas) are well characterized whereas to the best of our knowledge very limited data exist regarding extrapulmonary NECs. Such data mainly are derived from single-institution or small database studies limited by size and/or the sites evaluated. [3] [4] [5] [6] [7] The largest of these prior studies, the NORDIC NEC study, included 305 extrapulmonary NEC cases limited to the gastrointestinal tract. 8 Therefore, several concerns and questions regarding differences in epidemiology and the clinical behavior of extrapulmonary NEC and lung NEC and implications of morphological subtypes remain unanswered.
Although lung NECs typically are associated with a strong history of smoking, recent studies have suggested that the association with smoking for extrapulmonary NECs is weaker. 9, 10 Compared with lung NECs, the incidence of brain metastases appears to be lower in extrapulmonary NECs. 11, 12 In addition, although some studies have suggested similar objective response rates to platinum-based chemotherapies irrespective of site of origin of NEC, other studies have suggested otherwise. 13, 14 Thus, the clinical implications of the primary site of origin of poorly differentiated NECs remains to be elucidated. Epidemiological data concerning stage at diagnosis and survival according to different primary tumor sites and stage within gastrointestinal NECs and other extrapulmonary NECs are completely lacking, thereby hampering current clinical decision making. Although some data do not suggest differences in outcomes between patients with large cell and small cell NEC, a recent Dutch registry study suggested better outcomes for large-cell subtypes that need to be explored further. [15] [16] [17] [18] Finally, extrapulmonary NEC of unknown primary site represents approximately 10% of all poorly differentiated cancers of an unknown primary site, yet to our knowledge very little is known regarding this subset. 19, 20 As discussed in a recent series concerning rare cancers, the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) program provides a rich resource to help shape treatment guidelines in such situations. 21 Therefore, in the current study, we used the SEER program to comprehensively define the demographic, clinical, and prognostic features of poorly differentiated NECs.
MATERIALS AND METHODS
Data were retrieved from the SEER database based on the November 2014 submission for cases with tumors of malignant behavior and known patient age for cases diagnosed between the inception of the SEER program in 1973 until December 31, 2012. Poorly differentiated NECs were identified using the International Classification of Diseases for Oncology, 3rd Edition (ICD-O-3) morphology codes as detailed in Supporting Information Table 1 and classified as per the SEER historical staging system as localized, regional, and distant. Sites of origin were classified into respiratory, gastrointestinal, or unknown primary site (ICD-O-3 topography code C80.9), with the rest being grouped into NECs of other sites.
Statistical Analysis
Statistical calculations were performed using SEER*Stat software (version 8. Demographic and tumor characteristics were compared using the chi-square test. Patient characteristics were described using the entire cohort (see Supporting Information Table 2 ) and also the SEER 18 cohort (Table  1) separately, which is the latest registry grouping (2000) (2001) (2002) (2003) (2004) (2005) (2006) (2007) (2008) (2009) (2010) (2011) (2012) to reflect the most recent trends. One-way analysis of variance, the Kruskal-Wallis test, and the MannWhitney U test or Student t test for unpaired data were used for comparison of means or distributions of continuous variables between groups depending on the distribution of the variable; survival was measured using the Kaplan-Meier method and compared using the log-rank test. The Cox proportional hazards model was used for comparing the effects of prognostic variables on survival.
The proportionality assumption was tested by including time-dependent covariates in a separate model. All differences were considered statistically significant if the 2-sided P value was < .05.
RESULTS

Patient Characteristics
In the entire cohort, 87,997 of the patients (54%) were men. Approximately 87.8% were white, 8.3% were black, and remaining patients were of other races (see Supporting Information Table 2 ). Similar trends were noted in the SEER 18 cohort as well ( Table 1 ). The primary tumor site varied significantly according to sex (P<.001). Lung NEC, the majority of gastrointestinal NECs, NECs of urinary sites, and those of unknown primary site were more common among males (Table 1 ) (see Supporting Information Table 2 ). Racial differences were present, with lung NECs and urinary bladder NECs found to be more common in white individuals whereas gastrointestinal NECs were slightly more common in black individuals (Table 1 ) (see Supporting Information Table 2 ). The median age at diagnosis was 67 years (standard deviation, 10.9 months). The median age at the time of diagnosis varied significantly by site of origin (P<.0001), ranging from age 48 years for cervical NEC to age 74 years for bladder NEC (Table 2 ). In patients with known staging, significant differences were noted with regard to stage of disease at the time of diagnosis according to primary tumor site (P<.0001). Approximately 70% of patients with NECs of the lung, ovary, and pancreas had distant stage of disease at the time of diagnosis in contrast to only 24% of those with NECs arising in the urinary bladder and 35% with NECs of the cervix (Table 2) . for 41% of all NECs, and the upper gastrointestinal tract and the pancreas accounted for 23% and 20%, respectively, of NECs (Fig. 1C) . Approximately 3% of cases were coded as a liver primary tumor although it is likely that the majority of these were metastases. In the urinary system, the majority of NECs were of the urinary bladder (91%) (Fig. 2A) . In the female genital tract, approximately 54% arose from the cervix, 14% from the uterus, and another 22% from the ovaries (Fig. 2B ). In the male genital tract, nearly all cases were of the prostate (Fig. 2C) . Of the 162,983 cases included in the current study, 150,474 were small cell (92.4%) and 12,509 were large cell and other morphologies (7.6%). Of the total cases, 93.8% of small cell cases and 56.4% of large cell cases and other morphologies had the lung as their site of origin (Fig. 1A) . Of the large cell and other morphology cases, the majority (8219 cases; 65.7%) were coded as grade 3 or 4 NECs (ICD03 code 8246/3) without further morphological details and 30.7% (3844 cases) were coded as large cell carcinoma. Significant variations were noted with regard to morphological subtypes at major anatomical areas (P<.0001), with lung NECs having the highest percentage of small cell morphology (95.2%) and gastrointestinal NECs having the least (38.7%) (Fig. 1A) . Small cell morphology was dominant in esophageal, anal, gallbladder, and genitourinary primary sites (Figs. 1B and  1C ).
Survival
The median survival for all cases was 7.7 months. Significant differences in survival were noted according to stage at diagnosis, tumor site, and morphology (all P<.0001) (Figs. 3A and 3B ). Survival also was found to be significantly impacted by anatomical site and morphological subtype. For example, the median survival of all lung NEC cases was 7.6 months, in contrast to that at other sites of 14.5 months (Table 3) . It is interesting to note that NECs of unknown sites had the shortest survival (median survival, 2.5 months), possibly due to the metastatic nature of the majority of these cases. Within gastrointestinal NECs, those of the small intestine had the longest median survival (25.1 months) whereas NECs of 
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Cancer February 15, 2018 the pancreas had the shortest median survival (5.7 months). The 5-year survival rate was much lower for lung NECs (5.6%) and gastrointestinal NECs (13.1%) compared with other primary NECs (26.0%). Significant differences in survival also were found between different sites according to morphological subtype (P<.001) (see Supporting Information Table 3 ), with small cell histology being associated with worse median and 5-year survival at most sites. Similarly, gastrointestinal primary sites with localized stage with a predominance of small cell morphology (eg, esophageal and anal canal) had a lower 5-year survival rate than primary sites dominated by large cell and other morphologies (eg, stomach and colorectal) (Fig. 3) . Localized NECs had a median survival of 20.7 months, regional NECs had a median survival of 13.6 months, and NECs of distant disease had a median survival of 5.8 months. It is important to note that a significant percentage of patients without distant disease were alive after 5 years (Fig. 3) . The 5-year survival rate for patients with local disease stage ranged from 60% for those with NECs of the female genital tract and 40% to 50% for those with gastric, pancreatic, and colorectal NECs to 25% for patients with esophageal NECs. Even with regional disease, substantial rates of 5-year survival were noted in some sites, ranging from 28.5% for NECs of the female genital tract to 9.2% for esophageal NECs. Survival for distant stage NECs was poor irrespective of site, with only the female genital tract having a 5-year survival rate reaching 10%. An exception was NECs of the small intestine, which appeared to have better survival for all stages with an overall 5-year survival rate of 34.8%. We performed multivariate analysis of the impact of primary site while adjusting for prognostic factors influencing the survival of patients with NECs using the Cox proportional hazards model. The prognostic parameters included were disease stage, anatomical site, morphological subtype, sex, race, and year of diagnosis (divided into 2 equal periods: 1973-1992 and 1993-2012). The multivariate model confirmed the prognostic importance of the primary site (P<.0001) ( Table 3) .
DISCUSSION
High-quality data regarding poorly differentiated NECs are lacking due to the rare incidence of these malignancies outside of the lung and diverse primary sites. The current study is the largest study of poorly differentiated NECs published to date. Of the extrapulmonary NECs, gastrointestinal NECs and those of unknown primary site were found to be the largest groups. Significant differences in demographics, stage at diagnosis, and survival were noted based on the primary site and morphological subtype. These data thus question the present extrapolation of lung NEC treatment data to patients with extrapulmonary NECs. Ideally, future studies therefore should distinguish between lung NECs and extrapulmonary NECs and should consider stratifying patients according to the different primary sites. However, several challenges need to be considered: 1) the rare incidence and aggressive nature of these malignancies may make timely accrual onto studies difficult; and 2) the morphological classification of NEC often is difficult. As is evident from the results of the current study, NEC coded as neuroendocrine carcinoma without further details constitutes a significant percentage of all NEC cases, possibly reflecting the difficulty in making an accurate morphological classification. Such difficulties in the morphological assessment of poorly differentiated NECs also were illustrated by a recent study that demonstrated very low rates of agreement (33%) between pathologists regarding such a classification. 22 How do we overcome these challenges? One option would be to group sites based on percentages of morphological subtypes (eg "small cell predominant" and "large cell predominant") based on our data to improve accrual. Alternatively, large-scale, retrospective molecular and genomic analysis of these tumors may provide targets for basket trials that are agnostic to primary site and/or morphological subtype. For example, the recent early experience with rovalpituzumab tesirine, an anti-DLL3 antibody-drug conjugate that has demonstrated significant response in pretreated patients with small cell lung cancer, could be extended to individuals with extrapulmonary small cell cancers. 21, 23, 24 In the current study, a considerable percentage of patients without distant disease were alive after 5 years. Nearly one-half of the patients with localized cervical, gastric, colorectal, or pancreatic primary tumors still were alive after 5 years. Even among patients with regional disease, the 5-year survival rates were >20% for several primary sites. However, to the best of our knowledge, definitive recommendations for the management of patients with extrapulmonary NECs with resectable disease are lacking. Although some consensus guidelines recommend surgical resection in combination with chemotherapy and/or radiation, others have recommended surgical resection followed by adjuvant chemotherapy with radiation to be considered. 25, 26 Reflecting this, recent studies have come to conflicting conclusions regarding the role of surgery in the multimodality management of patients with localized gastrointestinal NECs. [27] [28] [29] It is likely that decisions regarding treatment will need to be individualized based on tumor site, but the results of the current study clearly demonstrate the need to have more concrete data and guidelines with which to improve outcomes for these patients.
The current study has several limitations. The SEER database does not classify patients according to the World Health Organization 2010 classification, nor does it have data regarding the Ki-67 proliferation index. Several known prognostic factors in cancer survival such as treatment, socioeconomic status, performance status, and comorbidities have not been included. The use of systemic chemotherapy also is not noted in the SEER database.
In spite of these limitations, the current study has important implications. To the best of our knowledge, it is the largest population-based study to describe the epidemiology and demographics of patients with poorly differentiated NEC. We observed significant differences with regard to demographics, and large variations in survival depending on the primary site and morphological subtype. A curative approach is possible for a substantial percentage of patients with localized or regional disease. In contrast, NEC of distant stage appears to be associated with a dismal prognosis and novel therapies are required.
FUNDING SUPPORT
This work and The University of Texas MD Anderson Cancer Center were supported by the National Institutes of Health through Cancer Center Support Grant P30CA016672.
